Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Benlysta | belimumab | Lupus nephritis | Reimburse with clinical criteria and/or conditions | Complete | ||
Saphnelo | anifrolumab | Systemic lupus erythematosus | Reimburse with clinical criteria and/or conditions | Complete | ||
Dupixent | dupilumab | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
Imfinzi | durvalumab | Biliary tract cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Yescarta | axicabtagene ciloleucel | Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Oxlumo | lumasiran | Primary hyperoxaluria type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
Orladeyo | berotralstat | hereditary angioedema (HAE) | Reimburse with clinical criteria and/or conditions | Complete | ||
Ultomiris | ravulizumab | Atypical hemolytic uremic syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | olaparib | gBRCAm, HER2-negative high-risk early breast cancer | Reimburse with clinical criteria and/or conditions | Complete |